Workflow
IGC Pharma(IGC)
icon
搜索文档
IGC Pharma(IGC) - 2021 Q2 - Quarterly Report
2020-11-20 21:06
收入和利润(同比环比) - 2020年9月30日止三个月,公司收入为12.5万美元,2019年同期为182.1万美元,同比下降93%,主要因新冠疫情限制[142] - 2020年9月30日止三个月,运营亏损为167.6万美元,2019年同期为128.8万美元,同比增加30%[142] - 2020年9月30日止三个月,净亏损为165.7万美元,2019年同期为117.9万美元,同比增加41%[142] - 2020年第三季度其他净收入减少约9万美元,降幅83%,2020年和2019年三季度其他收入分别约为1.9万美元和10.9万美元[149] - 2020年和2019年上半年营收分别约为70.9万美元和347万美元,降幅80%[150] - 2020年上半年其他净收入减少约11.7万美元,降幅63%,2020年和2019年上半年其他收入分别约为6.8万美元和18.5万美元[156] 成本和费用(同比环比) - 2020年9月30日止三个月,成本收入约为9.9万美元,2019年同期为179.3万美元,同比下降94%[142] - 2020年9月30日止三个月,销售、一般和行政费用增至148.3万美元,2019年同期为109.4万美元,增加约38.9万美元,增幅36%[142][146] - 2020年9月30日止三个月,研发费用约为21.9万美元,2019年同期约为22.2万美元,同比下降1%[142][147] - 2020年和2019年上半年成本分别约为63.7万美元和340.1万美元,降幅81%[150] - 2020年上半年销售、一般和行政费用增至323.8万美元,较2019年的234.3万美元增加约89.5万美元,增幅38%[153] - 2020年和2019年上半年研发费用分别约为44.1万美元和46.9万美元,降幅6%[155] 各条业务线表现 - 2020年9月30日止三个月,基础设施业务收入约为6.7万美元,2019年同期为154.7万美元[143] - 2020年9月30日止三个月,生命科学业务收入为5.8万美元,2019年同期为27.4万美元,产品组合有所变化[144] - 2020年和2019年上半年生命科学部门营收分别为64.2万美元和37.9万美元;基础设施部门营收分别为6.7万美元和309.1万美元[151] 管理层讨论和指引 - 公司计划在2021财年或2022财年初推出Herbo™、Hyalolex™、Holief™和Sunday Seltzer™产品线的在线销售[135] 其他没有覆盖的重要内容 - 2020年7月30日,公司收到FDA通知,可对IGC - AD1进行12名受试者的1期人体临床试验[137] - 截至2020年9月30日的六个月,现金及现金等价物降至115.1万美元,较3月31日的725.8万美元减少约610.7万美元,降幅84%[162] - 2020年和2019年上半年经营活动净现金使用量分别约为600万美元和440万美元;投资活动分别为19.5万美元和710万美元;融资活动分别为53万美元和1.8万美元[166] - 2020年上半年经营活动净现金使用量中,净亏损约350万美元,非现金项目约55万美元,经营资产和负债变动影响约350万美元[167] - 公司无未偿还的衍生金融工具、资产负债表外担保、利率互换交易或外汇远期合约等[173]
IGC Pharma(IGC) - 2021 Q1 - Quarterly Report
2020-08-19 20:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) 10224 Falls Road, Potomac, Maryland (Address of principal executive offices) (301) 983-0998 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | | Name ...
IGC Pharma(IGC) - 2020 Q4 - Annual Report
2020-07-11 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact Name of Registrant as Specified in Its Charter) Maryland (State or other jurisdiction of incorporation or organization) 10224 Falls Road, Potomac, Maryland (Address of Principal Executive Offices) (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock IGC NYSE American LLC (Name of e ...
IGC Pharma(IGC) - 2020 Q3 - Quarterly Report
2020-02-10 21:06
☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2019 ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) 20-2760393 (I.R.S. Emp ...
IGC Pharma(IGC) - 2020 Q2 - Quarterly Report
2019-11-05 22:53
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 Maryland (State or other jurisdiction of incorporation or organization) 20-2760393 (I.R.S. Employer Identification No.) 10224 Falls Road, Potomac, Maryland ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 (Address of principal executive offices) Commission file num ...
IGC Pharma(IGC) - 2020 Q1 - Quarterly Report
2019-08-09 01:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) 20-2760393 (I.R.S. Employer Identification No.) 20854 (301) 983-0998 (Registrant's telephone number, including area code) Common Stock, par value $0.0001 per share IGC NYSE American LLC Title of each class Trading symbol(s) Name of eac ...
IGC Pharma(IGC) - 2019 Q4 - Annual Report
2019-06-14 21:19
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact Name of Registrant as Specified in Its Charter) Maryland (State or other jurisdiction of incorporation or organization) (Title of each class) Common Stock IGC NYSE American LLC (Name of each exchange on which registered) (Trading Symbol) Securities registered pursuant to Section 12(g) of the Act: Common Stock Purchase Warrants 12224 Falls Road, Potomac, ...
IGC Pharma(IGC) - 2019 Q3 - Quarterly Report
2019-02-12 01:44
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of th ...